Φορτώνει......
Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
Systemic treatment of renal cancer (RCC) has undergone remarkable changes over the past 20 years with the introduction of immunotherapeutic agents targeting programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) axis, as a single-agent or combined with anti-CTLA-4 monoclonal antibodies (MoAb...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Int J Mol Sci |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
MDPI
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7369721/ https://ncbi.nlm.nih.gov/pubmed/32630154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21134691 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|